Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.89 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL11574957 | 1.00 | CA4 (0.89) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL1330792 | 0.94 | — | — | |
| Oxalic Acid SCHEMBL28222674 | 0.94 | CA4 (1.00) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL7776891 | 0.94 | — | — | |
| Oxalic Acid SCHEMBL40019 | 0.94 | — | — | |
| Oxalic Acid SCHEMBL16029775 | 0.89 | — | — | |
| Oxalic Acid SCHEMBL17511334 | 0.89 | CA4 (0.70) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL7530049 | 0.89 | CA4 (0.89) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL5909741 | 0.89 | CA4 (0.89) | CA4FAHD1MEN1LDHABLM | |
| Oxalic Acid SCHEMBL694299 | 0.89 | CA4 (0.89) | CA4FAHD1MEN1LDHABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1633709-A1 | ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1620427-A1 | CARBOXAMIDE DERIVATIVES AS ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6992092-B2 | substituted N-(indole-2-carbonyl)amides; antiischemic, anticholesterol, hypoglycemic, hypotensive agents; 5-chloro-1H-indole-2-carboxylic acid-[5-(1,2-dihydroxy-1-methyl-ethyl)-3-ethoxy-pyridin-2-yl]-amide | PFIZER INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6992101-B2 | N-(indole-2-carbonyl) and H-thieno[2,3-b]pyrrole-5-carboxamide anti-diabetic agents | PFIZER, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1562899-A2 | N-(INDOLE-2-CARBONYL)AMIDES AS ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040229916-A1 | Anti-diabetic agents | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| WO-2004096768-A1 | ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004092158-A1 | CARBOXAMIDE DERIVATIVES AS ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040157907-A1 | Anti-diabetic agents | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004041780-A2 | N-(INDOLE-2-CARBONYL) AMIDES AS ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | CA4 4857/4885FAHD1 1745/4885MEN1 4872/4885 |
| US-20040157907-A1 | Anti-diabetic agents | GPR119, INSR, IRS1 | CA4 2580/4885FAHD1 2194/4885MEN1 2918/4885 |
| US-20040229916-A1 | Anti-diabetic agents | GPR119, SLC5A1, GLP1R | CA4 1382/4885FAHD1 3430/4885MEN1 3379/4885 |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | IRS1, INSR, GPR119 | CA4 3412/4885FAHD1 926/4885MEN1 1810/4885 |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | AGTR2, AGTR1, AGT | CA4 4142/4885FAHD1 3145/4885MEN1 4523/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | CA4 4869/4885FAHD1 1548/4885MEN1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.